International Society for Infectious Diseases

EveLab Insight Advances Understanding of Skin Aging With AI-Driven Research

Retrieved on: 
Monday, June 5, 2023
Wellcome Trust Principal Research Fellow, The Digital Standard, Face, ISID, Ageing, Genoa Joint Laboratories, Woman, Anger, Research, Sadness, Dermatology, Eve M. Troutt Powell, International Society for Infectious Diseases, Human, International Society, Skin, Tongue and groove, Medical device, Cosmetics

Visible signs of aging, such as wrinkles, have been central to the scientific study of skin aging and are a key component of the multibillion-dollar skincare industry.

Key Points: 
  • Visible signs of aging, such as wrinkles, have been central to the scientific study of skin aging and are a key component of the multibillion-dollar skincare industry.
  • "The joint study has the potential to significantly enhance our understanding of skin aging characteristics," said Fudi Wang, Principal Research Scientist at EveLab Insight and co-author of the study.
  • "EveLab Insight has played a crucial role in the experiment by providing precise and stable quantitative AI skin detection technology."
  • By enhancing the understanding of skin aging, this study paves the way for more effective and targeted skincare solutions in the future.

Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113

Retrieved on: 
Friday, May 12, 2023
Volunteering, Gastrointestinal tract, Inflammatory Bowel Diseases, ISID, Weight loss, Inflammation, Colitis, Colon, Psoriasis, International Society for Infectious Diseases, Johnson & Johnson, Cytokine, TNBS, Peptide, Janssen Pharmaceuticals, Pharmaceutical industry, Vaccine, Protagonist

NEWARK, Calif., May 12, 2023 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") reported data from its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), on Phase 1 and preclinical studies of JNJ-2113 (formerly PN-235), presented by Janssen and co-authored with Protagonist, as an oral presentation at the International Societies for Investigative Dermatology (ISID) 2023 meeting in Tokyo, Japan. The presentation, "First-in-class oral peptide systemically targeting the IL-23 pathway," is available online at isid2023.org for registered users.

Key Points: 
  • The presentation, "First-in-class oral peptide systemically targeting the IL-23 pathway," is available online at isid2023.org for registered users.
  • Highlights of the data presented on JNJ-2113 include the following:
    JNJ-2113 is a macrocyclic peptide that binds to the IL-23 receptor with single digit picomolar affinity and demonstrated potent, selective inhibition of IL-23 signaling in human T cells.
  • Although peptides typically have low oral bioavailability, the high potency of JNJ-2113, along with its oral stability, indicated potential for systemic activity beyond the gastrointestinal tract in rat models of inflammation and colitis.
  • We look forward to the presentation of the Phase 2b FRONTIER 1 study data in adults with moderate-to-severe plaque psoriasis later this year."

AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update

Retrieved on: 
Thursday, May 11, 2023
Dostarlimab, Docetaxel, GSK, Autoimmunity, Therapy, ISID, The New England Journal of Medicine, CD122, G&A, Atopic dermatitis, NSCLC, Inflammation, BTLA, IGA, Patient, Investment, FIRST, International Society for Infectious Diseases, SAN, Annual general meeting, Webcast, British Journal of Dermatology, GPP, R, PD-1, Research, Rheumatoid arthritis, Immunoglobulin G, Vaccine, Pharmaceutical industry, Broadcasting, Cryptocurrency, Dermatology

“We’re excited about our progress as we continue to develop best-in-class antibodies across a number of high-value immune cell modulatory targets.

Key Points: 
  • “We’re excited about our progress as we continue to develop best-in-class antibodies across a number of high-value immune cell modulatory targets.
  • Collaboration revenue was $1.4 million for the three months ended March 31, 2023, compared to $1.0 million for the three months ended March 31, 2022.
  • The change is due to increased royalties recognized for sales of JEMPERLI and Zejula in the first quarter of 2023.
  • The G&A non-cash, stock-based compensation expense was $6.1 million for the three months ended March 31, 2023 and 2022.

Abeona Therapeutics Reports First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 11, 2023
PRV, Gene, Stargardt disease, Priority review, ISID, Drug discovery, Stargardt, Concha bullosa, AAV, Investment, International Society for Infectious Diseases, ADOA, Cell, Webcast, Research, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Safety, BLA, Society, Food, Pharmaceutical industry, Cryptocurrency, RDEB, List of Roman birth and childhood deities

CLEVELAND, May 11, 2023 (GLOBE NEWSWIRE) --  Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter of 2023 and provided an update on progress toward achieving key corporate objectives.

Key Points: 
  • Continues to make progress toward Biologics License Application (BLA) submission for EB-101 in late-2Q/early-3Q 2023; submitted request for pre-BLA meeting
    Reiterates cash runway guidance into 3Q 2024, beyond anticipated timing for EB-101 BLA potential approval
    CLEVELAND, May 11, 2023 (GLOBE NEWSWIRE) --  Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter of 2023 and provided an update on progress toward achieving key corporate objectives.
  • The Company has been granted pre-Investigational New Drug Application meetings for two of its programs to take place in the second quarter of 2023.
  • “Our operating cash burn for the first quarter of 2023 and projected operating cash burn for the second quarter of 2023 include BLA submission and personnel costs, which we expect will be substantially lower in the second half of 2023,” said Joe Vazzano, Chief Financial Officer of Abeona.
  • License and other revenues in the first quarter of 2023 were nil, compared to $0.3 million in the first quarter of 2022.

Abeona Therapeutics Announces Additional Phase 3 VIITAL™ Study Results for EB-101 Presented at the International Societies for Investigative Dermatology 2023 Meeting

Retrieved on: 
Thursday, May 11, 2023
ISID, RDEB, Quality of life, Concha bullosa, Blister, Stanford University School of Medicine, VII, International Society for Infectious Diseases, Itch, Principal, Wound healing, Dermatology

CLEVELAND, May 11, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an oral presentation of additional data from the Company's pivotal Phase 3 VIITAL™ study evaluating its investigational EB-101 for recessive dystrophic epidermolysis bullosa (RDEB).

Key Points: 
  • CLEVELAND, May 11, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an oral presentation of additional data from the Company's pivotal Phase 3 VIITAL™ study evaluating its investigational EB-101 for recessive dystrophic epidermolysis bullosa (RDEB).
  • The data presentation occurred earlier today during the inaugural International Societies for Investigative Dermatology (ISID) Meeting in Tokyo, Japan.
  • In addition to significantly reducing pain, patient-reported outcomes related to itch and blistering showed significantly greater improvement with EB-101 treatment.
  • EB-101 was shown to be well-tolerated with no serious treatment-related adverse events observed, consistent with past clinical experience.

Late-Breaking Turn Biotechnologies Presentation at ISID to Show Cell Reprogramming with ERA™ Technology Renews Skin

Retrieved on: 
Wednesday, May 10, 2023
Matrix metalloproteinase, Paul Khavari, ISID, Matrix metalloproteinase inhibitor, Regeneration, Research, Cell, Messenger, ERA, Cellular senescence, Oxidative stress, International Society for Infectious Diseases, Extracellular matrix, ECM, Wound healing, Shinjuku, Epigenetics, Shinjuku NS Building, Skin, JST, Medical device, Dermatology, Ageing

MOUNTAIN VIEW, Calif., May 10, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell reprogramming company developing novel mRNA medicines for untreatable, age-related conditions, has been invited to present data showing that its epigenetic reprogramming technology rejuvenates human skin.

Key Points: 
  • MOUNTAIN VIEW, Calif., May 10, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell reprogramming company developing novel mRNA medicines for untreatable, age-related conditions, has been invited to present data showing that its epigenetic reprogramming technology rejuvenates human skin.
  • Turn Bio's late-breaking abstract was accepted for presentation during the prestigious International Societies for Investigative Dermatology (ISID) Meeting, in Tokyo, Japan.
  • Data will show that transient reprogramming with Turn Bio's Epigenetic Reprogramming of Aging (ERA™) technology rejuvenates cells within the extracellular matrix (ECM), resulting in comprehensive changes related to improved skin quality and structure.
  • Turn Bio data will be presented by Dr. Edward Hsia, vice president of Dermatology at Turn Bio.

ASLAN Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, April 28, 2023
Abstract, Purchasing, Partnership, Executive director, Leo Pharma, Marketing, ISID, ASLN, ADS, TMO, Atopic dermatitis, Thermo Fisher Scientific, Neck, Associate, HCP, Sale, Yale School of Medicine, Alopecia areata, Development, Paul Khavari, Type 2, Journal, MD, Patient, Investment, International Society for Infectious Diseases, SAN, Autoimmune disease, Sanofi, Power purchase agreement, IL4R, Tralokinumab, Research, AD, NYSE, Safety, Pharmaceutical industry, Cryptocurrency, Video game, Head, Dermatology, AA

“We have also advanced farudodstat into a Phase 2a, proof-of-concept study in alopecia areata (AA) expected to commence enrollment in the second quarter of 2023.

Key Points: 
  • “We have also advanced farudodstat into a Phase 2a, proof-of-concept study in alopecia areata (AA) expected to commence enrollment in the second quarter of 2023.
  • The trial will recruit around 60 AA patients in the US and enrollment is expected to begin in the second quarter of 2023.
  • Research and development expenses were $14.1 million in the first quarter of 2023 compared to $9.4 million in the first quarter of 2022.
  • General and administrative expenses were $4.0 million in the first quarter of 2023 compared to $2.5 million in the first quarter of 2022.

ASLAN Pharmaceuticals Announces Four Abstracts on Eblasakimab and Farudodstat, Including Two Late-Breakers, to be Presented at the 1st International Societies for Investigative Dermatology Meeting

Retrieved on: 
Monday, April 24, 2023
Learning, Abstract, Neuron, Psoriasis Area and Severity Index, ASLN, Hair, DHODH, Head, Research, Neck, Immune privilege, MRGPRX2, Paul Khavari, Journal, Patient, International Society for Infectious Diseases, SAN, Interleukin, Drug development, Itch, Cytokine, AD, Pharmacology, Skin, JST, Medical imaging, Copper, Pharmaceutical industry, EASI, ISID

Two further abstracts on eblasakimab, which were earlier accepted for presentation at the ISID meeting, have been published online in the Journal of Investigative Dermatology.

Key Points: 
  • Two further abstracts on eblasakimab, which were earlier accepted for presentation at the ISID meeting, have been published online in the Journal of Investigative Dermatology.
  • “The abstracts published today highlight the potential of eblasakimab to offer important differentiated benefits for AD patients.
  • Spontaneous neuronal activity was not impacted by IL-13 treatment but was increased with IL-4 treatment, which was also effectively reduced by eblasakimab.
  • This indicates that direct impact on neuronal responses may contribute to reduction of chronic itch demonstrated in AD patients treated with eblasakimab.

Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 29, 2023
Biologics license application, CLN1, Business development, PRV, Priority review, ISID, Drug discovery, Rett syndrome, Stargardt, Bristol Myers Squibb, Holocene, Concha bullosa, AAV, MSHS, Rare, Dermatology, Eye, Orphanet Journal of Rare Diseases, Patient, Investment, International Society for Infectious Diseases, Ophthalmology, ADOA, Congress, Retinoschisis, FDA, Research, Therapy, Regulation of tobacco by the U.S. Food and Drug Administration, IND, Global marketing, BLA, Food, Wound healing, Medical imaging, Pharmaceutical industry, Vaccine, Cryptocurrency, Stargardt disease, RDEB, List of Roman birth and childhood deities

NEW YORK and CLEVELAND, March 29, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2022 and provided an update on progress toward achieving key corporate objectives. The Company will host a conference call and webcast today, March 29, 2023, at 8:30 a.m. ET, to discuss its financial results and business update.

Key Points: 
  • ET, to discuss its financial results and business update.
  • The Company currently plans to submit a BLA for EB-101 in late second quarter to early third quarter of 2023.
  • Abeona appointed Dmitriy Grachev, M.D., Ph.D., as Chief Medical Officer and Madhav Vasanthavada, Ph.D., M.B.A. as Vice President, Business Development.
  • Abeona Therapeutics will host a conference call and webcast today, March 29, 2023, at 8:30 a.m.

Run With Peter-Run for Research Raises $250K to Advance Medical Research

Retrieved on: 
Tuesday, June 21, 2022
Practice Management, Sports, Managed Care, Health, Running, Philanthropy, Fitness & Nutrition, Fund Raising, Breast cancer, Memorial Sloan Kettering Cancer Center, Health, Running, International Society for Infectious Diseases, Infection, American Heart Association, Research, AML, Foundation, Breast Cancer Research Foundation, Endurance, Physician, Exercise, International Society, Hospital, Cancer, Acute leukemia, Patient, Awareness, ICU, Organization, Sports medicine, Pharmaceutical industry, Sermo

Sermo CEO Peter Kirk announces today the successful completion of the first-ever global, doctor-led running event, Run with Peter -Run for Research .

Key Points: 
  • Sermo CEO Peter Kirk announces today the successful completion of the first-ever global, doctor-led running event, Run with Peter -Run for Research .
  • Run With Peter is an initiative to empower and inspire a global community of physicians, healthcare teams and partners who run (or walk) together to raise money in support of medical research.
  • Sermo will donate $250,000 to support various medical research causes, which were chosen by physicians participating in Run with Peter.
  • Upon registration, participants selected the area of medical research and actual foundations they would like to receive a portion of the overall donation.